DAY 2-Saturday, Feb. 8, 2014

NEW HORIZONS FORUM

Managing glaucoma with personalized
IOP monitoring treatment

Patients with glaucoma can expect both transformative and disruptive changes in the monitoring and treatment of their disorder over the next 5 years, predicted Robert N. Weinreb, MD, chairman of ophthalmology and director of the Shiley Eye Center and Hamilton Glaucoma Center, University of California, San Diego (UCSD). Dr. Weinreb delivered the first Drs. Henry and Frederick Sutro Memorial Lecture here at the 3rd Annual Glaucoma 360 New Horizons Forum. » MORE

What's new in glaucoma device,
drug therapy advancements

Given that a glaucoma treatment is now a $5 billion market, an ophthalmic company starts talking to venture capital firms when it needs that first $1 million to move a product from clinical trials to realized treatment, said Emmett Cunningham, MD, PhD, MPH, partner at Clarus Ventures. He gave a brief overview of recent new product advances. » MORE

Dr. Lindstrom: From building blocks
to ophthalmic innovation

"I'm probably the only person to have a father angry that his son went to medical school," quipped Richard L. Lindstrom, MD. As he was interviewed by Gil Kliman, MD, Dr. Lindstrom recalled that he was primed for the construction business by his father, before medicine chose him. » MORE

Glaucoma Research Foundation update: Adaptive optics and glaucoma biomarkers

In a rapid-fire update, Alfredo Dubra, PhD, presented new glaucoma findings using adaptive optics and glaucoma biomarkers. Dr. Dubra, assistant professor and co-director, Advanced Ocular Imaging Program, Medical College of Wisconsin, highlighted recent results from the "truly collaborative" research he and three other recipients—Jeffrey Goldberg, MD, PhD; Andrew D. Huberman PhD; and Vivek J. Srinivasan, PhD—of the Glaucoma Research Foundation's Catalyst for a Cure grants have produced in less than 2 years. » MORE